Sentences with phrase «with new cell»

Last summer, a group of researchers were able to break the world record for laboratory efficiency by reaching 44.7 % with a new cell, with 50 % as the ultimate goal.

I can't really picture that first convo with her new cell mate going too well:

With every new eBook reader in the market, with every update to the software readers Amazon, Barnes & Noble or Kobo offers, and with every new cell phone and tablet that enters the market, the playing field becomes harder to control.

If so, you might identify with Tawny Lindholm, a recent widow grappling with a new cell she believes was a gift.

Best friend Sydney (Meade) has been obsessed with a new cell phone game / app called Nerve.

Vitamin B6 helps with new cell formation, making it essential for brain, cardiovascular, nervous system, and skin health.

Ackerman said that this new understanding combined with new cell - free techniques — making hundreds of designer enzymes a day with components derived from cells — will speed the development of task - specific enzymes.

With PhD student Carmen Lorenz at the MDC and the Berlin Institute of Health (BIH), he teamed up with other MDC researchers and scientists from France to come up with a new cell - based system to carry out drug screens.

«RNAi is very promising as a therapy, but the efficacy of the treatment declines over time with each new cell division,» Jose said.

Next, the team set about regrowing the «flesh» of the organ by coating the inner surfaces of the scaffold with new cells.

Every tissue of our body has stem cells that continuously divide to replenish the body with new cells.

Stem cells, which have to divide regularly to regenerate tissues with new cells, can produce telomerase, but not the amount required to counteract the shortening of telomeres that accumulates with aging: over time, the tissues have fewer fresh cells and they lose their regenerative capacity.

There is no plan for what to do with the new cells.»

Cancer stem cells are the ultimate source of the tumor, consistently supplying it with new cells.

Stem cells, which have to divide regularly to regenerate tissues with new cells, can produce telomerase, but not the amount required to counteract the shortening of telomeres that accumulates with ageing: over time, the tissues have fewer fresh cells and they lose their regenerative capacity.

Firstly, the majority of evidence indicates that cells go back to normal levels within a few hours, which is much too quick for them to be «replaced» with new cells.

Not exact matches

But even with steep discounts and quality service, it takes an awful lot to get a customer to go through the hassle of switching from one cell service to another — especially to a new wireless service of unknown quality and no track record.

So researchers, with limited success, have tried to build such a GPS directly into a new type of biological assassin called a «CAR - T cell.»

Matanov, who had hiked a New Hampshire mountain with Tamerlan Tsarnaev to «train like, and praise, the «mujahideen,»» according to court papers, deleted searches related to the attacks from his computer, tried to dispose of cell phones he had used to contact the brothers, and denied knowing much about the pair in interviews with police.

So to keep its scooters running as long as advertised, Gogoro plans to pull power cells from circulation once the battery reaches 80 percent of capacity and replace it with a fresh, new unit.

Hyundai unveiled a near production version of its new fuel cell SUV with a driving range of more than 800 km per charge under European standards, nearly double the 415 km for its current Tucson fuel cell SUV.

To read his blog is to watch the growth of a human being: You see Ev nearly lose his company, bring it back from the dead, strike it big, struggle with the tech support for his new cell phone, and get married.

Biotech giant Gilead Sciences is beefing up its cancer drug portfolio with a $ 11.9 billion deal to buy Kite Pharma, a company focused on a groundbreaking new class of treatments that turns the body's own immune cells into targeted blood cancer killers.

The new indication puts Kymriah in direct competition with Gilead Sciences» Yescarta, which was approved by the U.S. Food and Drug Administration in October for treatment of adults with diffuse large B - cell lymphoma who have failed to respond to other treatments.

When sitting in my dark gray cell with my books, newspapers and magazines, while writing, reading and researching the tech sector, I would visualize myself in Silicon Valley at partner meetings, with my new startup, raising capital from prominent venture capitalists.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The biotech has been jockeying against main rivals Novartis and Juno to secure a first - to - market advantage with the groundbreaking new medical tech, which turns patients» immune cells into souped - up, re-engineered cancer killers that are then reintroduced into the body.

While the company's service is typically offered in the home, it is getting set to debut a new universal hotspot service for anyone with a cell phone.

Tesla CEO Elon Musk confirmed today with a tweet that Tesla has no plans to use its new 2170 lithium ion cell...

Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR - V7 protein expression test using Epic Sciences» non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration - resistant prostate cancer.

We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer.

Sprint signed new long - term contracts with cell tower companies to facilitate its build - out.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmCell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmcell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmcell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

The startup describes itself as a deep data platform for the study of exosomes, which are small lipid vesicles — air - or fluid - filled cavities — that are excreted from cells and which deliver information that Mantra plans to use to come up with new drug therapies.

The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

He hopes Medicine by Design's collaboration with Rotman will help cultivate a new generation of bioscience entrepreneurs who will strengthen Toronto as a global hub for stem cell - based therapies and help Canada realize its full potential in the field.

This includes a stem cell research centre, a network of drug discovery institutes and a # 20 million global clinical development fund dedicated to supporting Phase I and II clinical trials; and a # 2 million collaboration between University of Cambridge and University College London that will use donated cells from people with Alzheimer's to test potential new treatments

Research on a new «gene editing» technology known as CRISPR — which theoretically allows any cell or organism to have its genome altered — is advancing exponentially, with early research ongoing on human embryos created for that purpose.

Benedict argued that non-conjugal reproduction such as in vitro fertilization had created «new problems» ¯ the freezing of human embryos, for instance, and the selective abortion of medically implanted embryos, together with pre-implantation diagnosis, embryonic stem - cell research, and attempts at human cloning.

Meanwhile, the February 2 issue of the New Scientist noted the work being done with stem cells to create «female sperm» and «male eggs.»

Two new papers have just been published documenting further advances with induced pluripotent stem cells --- stem cells that are «embryonic - like» but that are not derived from embryos.

The door to our prisons have been unlocked, but often we stay there inside our prison cells decorating it with curtains and a new paint job.

Adult stem - cells are now being used to grow new body - parts that can be implanted with no risk of rejection, the latter being the single largest cause of organ rejection and subsequent death.

I may regret even entering this, but... it looks like that quote of his is simply saying that a bowlful of DNA can't replicate itself without being part of a living cell and having new material to work with.

The Catholic Herald: US Franciscan province offers «text - a-prayer-intention» service Often, prayer intentions are offered with hands folded, but a new service allows hands and fingers to move freely - provided a cell phone is handy.

In November the Lancet published the results of an international research project whereby a Colombian lady received a new trachea (windpipe) which had been grown from a donor trachea (as it were, a «scaffold») repopulated with stem cells, for the very first time, from the patient's own body.

Unlike the controversial method of tissue harvesting that requires some human embryos to be destroyed, the new cloning technique can use a patient's own skin cells — combined with an unfertilized human egg — to create tissue with a DNA match.

In all likelihood, soon after he is sworn in, federal dollars will start flowing toward research on new embryonic stem - cell lines, bringing with it new battles to fight.

Not surprisingly, President Obama received high marks from the journal, largely because his response to the question of whether he would lift Bush's ban on the federal funding of new embryonic stem - cell lines is in line with the view of most in the scientific community.

Religious thinkers hold these general positions with differing degrees of intensity and emphasis in defining their positions regarding the genetic modification of cells and the new reproductive technologies that seek eugenic solutions to procreative problems.